AnaptysBio drops another indication for lead drug after it fails a second PhII study in 12 months
AnaptysBio’s lead drug has failed another mid-stage study, leading to its discontinuation in acne.
The biotech revealed Monday afternoon that its anti-IL-36R antibody imsidolimab did not show efficacy over placebo in either primary or secondary endpoints for its Phase II trial. Though AnaptysBio did not reveal p-values, patients on placebo saw greater numerical reductions of facial acne than either of the low- or high-dose imsidolimab cohorts.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.